2HG MRS in glioma v1.0
Research type
Research Study
Full title
Clinical 2-hydroxyglutarate magnetic resonance spectroscopy in glioma
IRAS ID
252870
Contact name
Adam Waldman
Contact email
Sponsor organisation
University of Edinburgh
ISRCTN Number
ISRCTN18300486
Clinicaltrials.gov Identifier
N/A, N/A
Duration of Study in the UK
2 years, 0 months, 1 days
Research summary
Gliomas are the most common brain cancer in adults. Lower grade diffuse gliomas (LGG) behave variably depending on abnormalities, called mutations, in the tumours genes that determine how aggressively it will behave and respond to treatment. These can be characterised by performing specific tests on glioma tissue that has been removed by a surgeon. It would be useful to have this valuable information for treatment planning at the time of diagnosis, but it is currently only available after the patient has had their operation. One of these mutations is for the enzyme isocitrate dehydrogenase (IDH), which causes very specific changes in the internal chemistry (‘metabolism’) of the glioma, and the production of a particular biochemical or ‘metabolite’ called 2-hydroxyglutarate (2HG) which is not normally present. 2HG can now be detected in the living brain using a specialist type of MRI scan called spectroscopy. MRI spectroscopy for 2HG is currently mostly used in research.
Our project aims to adapt and test the feasibility and reliability spectroscopy for detecting 2HG and hence identify gliomas with IDH mutation in the hospital setting, for improved treatment planning in patients.
Our study will:
Optimise 2HG spectroscopy acquisition and analysis methods using test objects (‘phantoms’) which contain known concentrations of metabolites.
Perform a single optimised 2HG spectroscopy scan in 20 patients with LGG, and compare the results with IDH mutation in tissue acquired from surgery.
By generating ‘maps’ of 2HG levels in the tumour and targeting tissue sampling (biopsy), compare variation in 2HG in different tumour regions against genetic and biochemical tissue features from these regions.REC name
East of England - Cambridge South Research Ethics Committee
REC reference
24/EE/0081
Date of REC Opinion
7 May 2024
REC opinion
Further Information Favourable Opinion